Foghorn Therapeutics Inc
Veridion Score
Composite trend over time
Why is FHTX moving today?
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for FHTX.
FHTX insider activity
Foghorn Therapeutics Inc
9 insiders bought in the last 90 days
Net buying: $31.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-25 | 2026-06-24 | Gallagher Neil | Insider | buy | $4.08 | 28,000 | 28,000 | $114K | SEC Form 4 |
| 2026-06-25 | 2026-06-24 | Duty Stuart | Insider | buy | $4.08 | 28,000 | 28,000 | $114K | SEC Form 4 |
| 2026-06-25 | 2026-06-24 | Mendelsohn Michael | Insider | buy | $4.08 | 28,000 | 28,000 | $114K | SEC Form 4 |
| 2026-06-25 | 2026-06-24 | Biller Scott | Insider | buy | $4.08 | 28,000 | 28,000 | $114K | SEC Form 4 |
| 2026-06-25 | 2026-06-24 | Cole Douglas G. | Insider | buy | $4.08 | 28,000 | 28,000 | $114K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 12 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFHTX contract awards, year to date.
Public federal awards linked to this ticker.
FHTX lobbying filings, year to date.
Registered lobbying filings matched to Foghorn Therapeutics Inc.